Gilead’s Yescarta Bests Long-Time Standard of Care in R/R LBCL Overall Survival

Yescarta is the first treatment in nearly 30 years to improve overall survival in relapsed/refractory large B-cell lymphoma R/R LBCL, according to Gilead’s Kite Pharma.